Cannabinoids and Neuropsychiatric Disorders

Cannabinoids and Neuropsychiatric Disorders - Advances in Experimental Medicine and Biology

1st Edition 2021

Hardback (18 Dec 2020)

  • $192.23
Add to basket

Includes delivery to the United States

10+ copies available online - Usually dispatched within 7 days

Publisher's Synopsis

This volume highlights the recent advances in the understanding of the endocannabinoid system and the likely benefit from the therapeutic effects of cannabinoid treatment in a variety of health issues.

Archeological evidence has shown that Cannabis has a long history of use for multiple purposes, including the treatment of medical conditions. The primary active constituent of the hemp plant Cannabis sativa, delta 9-tetrahydrocannabinol (Δ9-THC), causes euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concentration and impairment of memory, among other effects. Despite these undesirable effects, signaling is mostly inhibitory and suggests a putative role for cannabinoids as therapeutic agents by managing several diseases where inhibition of neurotransmitter release would be beneficial.

The themes of this book have been edited and  written by world-leaders in the field, The contents of the volume aims at readers from a range of academic and professional disciplines, such as biomedicine, several areas of biology, neurology, clinical medicine and pharmacy.

Book information

ISBN: 9783030573683
Publisher: Springer International Publishing
Imprint: Springer
Pub date:
Edition: 1st Edition 2021
Language: English
Number of pages: 153
Weight: 533g
Height: 254mm
Width: 178mm
Spine width: 11mm